Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01423110 · ClinicalTrials.gov registry record · Phase 2
Efficacy, Safety and Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 14
- Enrollment target
NCT01423110: Completed Phase 2 study, sponsored by Novartis Pharmaceuticals.
NCT01423110 is a Phase 2 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 14 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (89% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01423110, a Phase 2 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 14 participants
- Enrollment target
Study Summary
This study will assess the efficacy, safety and tolerability of BYM338 in patients with sporadic Inclusion Body Myositis
Primary Outcome
Change in thigh muscle volume
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL BYM338
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2011-08 |
| Est. Completion | 2012-05 |
| Phase | Phase 2 |
What the finished NCT01423110 record still lists
NCT01423110 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (89% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01423110 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01423110 about?
NCT01423110 is a clinical study titled "Efficacy, Safety and Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis". This study will assess the efficacy, safety and tolerability of BYM338 in patients with sporadic Inclusion Body Myositis
What is the current status of trial NCT01423110?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 14 participants. The study started on 2011-08. Estimated completion is 2012-05.
What interventions are being tested in trial NCT01423110?
The interventions under investigation include: Placebo (BIOLOGICAL), BYM338 (BIOLOGICAL).
Who is sponsoring clinical trial NCT01423110?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01423110's enrollment target sits among peer trials
14 1941st of 2000 higher than 54 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia